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Background. Vernal keratoconjunctivitis (VKC) is a rare inflammatory disease involving the ocular surface, with seasonally
exacerbated symptoms. Both type-1 and type-4 hypersensitivity reactions play a role in the development of VKC. Purpose.(e aim
of the present study was to assess the presence and evaluate the concentration of the vascular endothelial growth factor (VEGF) in
tear and blood samples from patients with VKC, during the acute phase, based on the histopathological vasculostromal structure
of the tarsal papillae. Methods. Two groups of children aged between 6 and 16 years of life were enrolled: 21 patients (16 males,
76%) affected by VKC, tarsal or mixed form, and 13 healthy children (5 males, 38%) used as controls. Blood and tear samples were
obtained from all patients, in order to specifically assess the presence of VEGF. Statistical analyses were performed with one-way
ANOVA, followed by post hoc comparisons with the Bonferroni tests. Pearson’s correlation was chosen as statistical analysis to
assess the relationship between the expression levels of VEGF in tears and blood and the clinical parameters measured. Results.
Comparing the 2 groups for VEGF concentration, a statistically significant difference was found in tear samples: the mean value
was 12.13 pg/mL (±5.54 SD) in the patient group and 7 pg/ml (±4.76 SD) in controls (p< 0.05). However, no statistically sig-
nificant difference was found when comparing VEGF concentration in blood samples (p> 0.05), with amean value of 45.17 pg/mL
(±18.67 SD) in VKC patients and 38.08 pg/mL (±19.43 SD) in controls. Conclusions. (is pilot study highlights the importance of
lacrimal and vascular inflammatory biomarkers that can be detected in VKC patients during the acute phase, but not in healthy
children. (e small group of patients warrants additional studies on a larger sample, not only to further investigate the role of
VEGF but also to evaluate the angiogenic biomarkers before and after topical treatment.
1. Introduction
Vernal keratoconjunctivitis (VKC) is a rare (<1 :10.000),
chronic, bilateral, at times asymmetrical, often severe in-
flammation of the ocular surface. It was first described in the
ophthalmic literature as conjunctiva lymphatica more than
150 years ago. Subsequently, numerous authors referred to it
using different names, each one labeling one of the various
aspects of the disease [1–3]. VKC especially affects young
males, with an average age of onset of 6-7 years and a re-
ported male-to-female ratio varying from 4 :1 to 2 :1, and
tends to regress during or soon after puberty, disappearing
in the majority of cases around 4–10 years after onset. It is
more common in dry and hot climates, such as the Medi-
terranean area, Central Africa, West Africa, the Middle East,
Japan, the Indian subcontinent, and South America [3–6].
VKC is typically characterized by seasonal exacerbations,
although the most severe forms can suffer from perennial
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symptoms, and visual impairment may occur if the cornea is
involved. According to the predominant conjunctival dis-
trict involved, three forms of vernal keratoconjunctivitis
have been identified and described: tarsal (palpebral), limbal
(bulbar), andmixed type. In the first form, more prevalent in
Europe and the Americas, large papillae (>1mm) occur
predominantly at the upper tarsus and those with a size of
7-8mm are known as cobblestone papillae, constituting
from the vasculostromal structure of collagen types I and II
and proteoglycans [3–5]. (e limbal form, which is more
seen in Africa, is usually accompanied by limbal infiltrates
and Horner–Trantas nodules; the mixed type presents in-
termediate characteristics between the two. A recent study
has suggested an update to this classification that should
include a phenotype with a predominant corneal in-
volvement. Even though this was associated with nonspecific
alterations of the corneal epithelium, relevant changes were
measured by confocal microscopy and they were correlated
with the degree of photophobia reported by patients. Cor-
neal changes include punctate epithelial keratitis, epithelial
macroerosions, gelatinous limbal hypertrophy, and plaque
formation [3–5]. If untreated, the initial damage may lead to
the onset of oval-shaped epithelial defects, known as shield
ulcers, which are reported to occur in 3–11% of patients
[3–6]. (ese undoubtedly represent the most severe signs of
the disease, as they can have a heavy impact on the quality of
life and even cause visual impairment or lead to astigmatism,
keratoconus, corneal perforations, and scars. Although the
allergic nature of VKC has been accepted for a long time, its
exact aetiology and pathogenesis are still unclear. (e role of
hormonal factors is suggested by positive staining for oes-
trogen and progesterone receptors in the conjunctiva from
patients, predilection for male sex, and resolution after pu-
berty [3, 6, 7]. Genetic predisposition also contributes to the
development of this disease, and although no relationship has
been found yet between VKC and a particular genotype, the
constant and increased presence of eosinophils in blood, tears,
and conjunctival scrapings, the expression of a multitude of
mediators and cytokines, and the predominance of CD4 cells
locally suggest that VKC may be a phenotypic model of
upregulation of the cytokine gene cluster on chromosome 5q
[7–12]. In addition, multiple studies have investigated the
family history of allergic diseases (asthma, rhinitis, eczema,
urticaria, and dermatitis) and immunological diseases
(Hashimoto’s thyroiditis, type I diabetes, psoriasis, rheuma-
toid arthritis, and systemic lupus erythematosus), reporting
such an association in roughly half of the patients diagnosed
with VKC [3, 5, 6, 13, 14]. At this point, the accumulation of
a large amount of immunological data has established that the
pathogenesis of VKC is muchmore complex than amere type
1 hypersensitivity reaction, also involving IgE-independent
(type IV) mechanisms and cytokines, such as the interleukin
17 (IL-17) [7, 10, 12].
(e purpose of the present study was to assess the
presence and evaluate the concentration of vascular endo-
thelial growth factor (VEGF) in tear and blood samples of
patients affected by VKC, during its acute phase, comparing
the results with a control group, in order to evaluate the role
of VEGF in the pathogenesis of this disease.
2. Patients and Methods
(e study was performed at the Department of Sense Organs
of the “Policlinico Umberto I” and at the Department of
Pediatrics, Division of Allergy and Immunology, Sapienza
University of Rome. In accordance with the Helsinki Dec-
laration, all parents were informed about the use of their data
and informed consent was obtained. (e study also fully
obeyed the Good Clinical Practice guidelines and was ap-
proved by the Ethical Committee of our hospital, Sapienza
University of Rome (authorization Rif. CE: 4708, 9/11/2017;
Prot. Cod.: VKC06/2017).
We enrolled 21 children (16 males, 76%), aged between 6
and 16 years of life, affected by tarsal and mixed forms of
VKC (Figure 1; Table 1). (irteen healthy children (8 males,
62%) with negative skin prick test (SPT), without allergic,
ocular, and systemic disease, cross-matched for sex and age
with patients affected by VKC, were used as controls. At the
time of enrolment, a complete hematologic and cardiologic
examination was performed, systemic blood pressure was
determined, and blood samples were collected. A complete
ophthalmic evaluation was performed on both eyes through
a detailed medical and ocular history. (e eye examination
included the following:
(i) Best-corrected visual acuity (BCVA) for far and
near distance
(ii) Slit-lamp biomicroscopy
(iii) Intraocular pressure measurements
(iv) Dilated fundus examination
(e diagnosis and follow-up were performed by an expert
ophthalmologist through a score based on ocular signs such as
little and/or giant papillae, conjunctival hyperemia, keratitis,
and Horner–Trantas dots and on subjective ocular symptoms
such as itching, photophobia, foreign body sensation, tearing,
and mucous secretion according to the system described by
each variable. In this score, each variable was graded as
follows: 0� absent; 1� light; 2�mild; 3�moderate; and
4� severe [3, 9]. Patients with a total score ≥10 were included
in the study. Some authors subsequently expanded it by
including two supplemental parameters: the duration of
symptoms (0 if <1 year, 1 if >1 year, and 2 if >2 years) and
the worsening of symptoms in spring and summer (0 if not
present and 1 if present). Conjunctival scraping was also
performed, in order to further improve the diagnosis in
patients with VKC. Skin prick tests (SPTs) were performed on
each patient for common inhalants and food allergens
(Lofarma, Milan, Italy):Dermatophagoides pteronyssinus (Der
P), Dermatophagoides farinae (Der F), dog/cat dander, Olea
europaea, Lolium perenne, Alternaria alternata, Parietaria
officinalis, lactalbumin, β-lactoglobulin, casein, egg white and
yolk, soy, and cod fish. A positive SPT was defined by the
presence of a wheal more than 3mm respect to the wheal size
of the control (saline solution). Serum was obtained from the
peripheral blood samples collected from all the children in-
cluded in the study to evaluate the serum level of VEGF,
autoimmunity, ANA, and total IgE (Table 1). Blood samples
were obtained at enrolment. In both patients and controls,
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tear samples were obtained as follows: 20–50 µl of open eye
tears was gently collected from the external canthus of the
most affected eye using a capillary micropipette and avoiding
the tear reflex as much as possible.(e samples were placed in
Eppendorf Tubes, centrifuged at 160×g for 8min, and stored
at −80°C. (e samples were successively probed using three
microwell plate arrays.
3. VEGF Level Measurement
Lacrimal and serum VEGF levels in healthy and VKC pa-
tients were determined with the VEGF EIA Kit from Enzo
Life Sciences and following manufacturer’s instructions.
Briefly, 100ml of samples was mixed with 100ml of the assay
buffer and placed in each well of a 96-well plate.(emix was
then incubated for 18 h at 4°C. (e following day, each well
was rinsed with a washing buffer before adding 100ml of an
anti-VEGF antibody/well. (e antibody was incubated for
30min at 4°C. Afterward, 100ml of a substrate solution was
added and incubated for 30 minutes at room temperature
(RT) in the dark. After adding a stop solution, the optical
density at 450 nm was measured using the GloMax-Multi
Detection System (Promega, Milan, Italy). (e fluorescence
intensity of the assay buffer was subtracted from each ex-
perimental sample.
4. Statistical Analysis
Data obtained were used for statistical analysis. Quantitative
variables were summarized with mean and standard de-
viation (SD). (e differences between groups were evaluated
by Fisher’s chi-square test or test. (e correlations between
clinical, demographic, and biological parameters were
performed with Spearman’s rho.(e results are expressed as
means± SD and 95% confidence intervals (95%CIs). Sta-
tistical analyses were performed with one-way ANOVA,
followed by post hoc comparisons with the Bonferroni tests.
Calculation of Pearson’s correlation was also chosen as
statistical analysis. Values were relieved to assess the re-
lationship between the expression levels of VEGF in tears
and blood and the clinical parameters measured. A p val-
ue< 0.05 was considered statistically significant. Statistical
analysis was conducted through the SPSS 18.0 software
(Statistical Package of Social Sciences, Chicago, IL, USA).
5. Results
(e study included 21 patients (16 males and 5 females) aged
between 6 and 16 years of life (mean 8.62; SD± 2.65), af-
fected by tarsal and mixed forms of VKC, and thirteen
healthy children (8 males and 5 females) aged between 6 and
(a) (b)
Figure 1: Patient affected from vernal keratoconjunctivitis (VKC). (a) Mixed form with cornel signs limbar neovascular and (b) tarsal
papillae on the superior conjunctiva.
Table 1: Demographics and clinical grading of 21 vernal keratoconjunctivitis (VKC) patients.
Characteristics of VKC patients
Sex 16 males (76%) 5 females (24%)
Age (from 6 to 16 years) Mean 8.62 SD± 2.65
VA (BCVA) 20/20 SD± 0.0
Atopic SPT 11 positive (52.4%); major allergens:house dust and grasses 10 negative (47.6%)
Family condition 12 (57%) familiar with allergic DS 3 (14%) familiar with autoimmune DS
VKC forms Tarsal: 13 (62%) Mixed: 8 (38%)
Vitamin D levels (VKC vs controls) (in ng/ml) 19.8± 6.7 vs 24.7± 6.5 Lower levels if compared to controls (p< 0.0001)
ANA positivity 30.8% Total IgE 4100UI/ml 46.1%
Photophobia (grade 4) 42.3% Secretion or tearing 28.8%
Foreign body sensation 25.4% Itching and conjunctival hyperemia 11.5%
SD: standard deviation; VA: visual acuity; BCVA: best-corrected visual acuity for far distance; SPT: skin prick test for several common inhalants and food
allergens; DS: diseases.
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15 years (mean 7.98; SD± 3.2). (e 2 groups for mean age
and gender were not statistically significant. According to
literature, VKC prevalence was higher in males than in
females (76% vs 24%) in the population we studied
[1, 3, 14, 15]. Allergological, serological, and lacrimal tests
were normal in the control group, while 11 VKC patients
(52.4%) showed positive Skin Prick Test (SPT) for several
common inhalants and food allergens. Fifty-seven percent of
patients were familiar with allergic diseases and 14% had
a parent with autoimmune disease. Comparing the 2 groups
after using the VEGF EIA kit for VEGF concentration,
a statistically significant difference was found in tear sam-
ples: the mean value was 12.13 pg/mL (±5.54 SD) in the
patients group and 7 pg/ml (±4.76 SD) in controls (p< 0.05)
(Figure 2). However, no statistically significant difference
was found when comparing VEGF concentration in blood
samples (p> 0.05), with a mean value of 45.17 pg/mL
(±18.67 SD) in VKC patients and 38.08 pg/ml (±19.43
SD) in controls (p � 0.29) (Table 2).
(e correlation of Pearson revealed an r value of −0.14,−0.18, −0.15, and −0.12 between the expression levels of
VEGF in tears and the clinical parameters giant papillae,
foreign body, conjunctival hyperemia, and itching, re-
spectively. Moreover, the correlation of Pearson showed an r
value of −0.28, 0.01, 0.04, and −0.03 between the expression
levels of VEGF in serum and the clinical parameters giant
papillae, foreign body, conjunctival hyperemia, and itching,
respectively. (ere were significant correlations between the
mean values of VEGF tears and the clinical parameters
(p< 0.05). However, the statistically significant correlation
was only identified between VEGF serum and giant papillae,
and there was no relationship between VEGF serum and the
other clinical parameters (Table 3).
6. Discussion
(e purpose of this study was to assess the presence and
evaluate the concentration of VEGF in tear and blood
samples of patients affected by VKC in acute phase in
comparison with the control group in order to assess the
pathogenic role of VEGF.
VKC is a rare, chronic ocular disease that affects chil-
dren, mainly involving males over females, and usually
regressing during or soon after puberty. (is aspect em-
phasizes the role of hormonal factors in the pathogenesis of
the disease, as pointed by several studies [3, 9, 15]. Although
VKC has been always regarded as an IgE-mediated disease,
the literature reports that roughly 50% of patients have
a positive SPT or high levels of serum IgE. Our data were in
line with these findings. (us, the IgE-mast-cell-mediated
process and (1 response are not enough to explain all the
mechanisms of the disease. (e role of (2 responses in
VKC has been studied for a long time, and VKC is actually
not regarded just as an ocular disease but as a systemic
disease with a T-cell-activated response. Many studies
underlined the role of single cytokines and mediators in the
development of the disease, such as the IL-17 and the
HMGB-1 [11–13, 15]. In the present study, we focused on
the assessment and quantification of the VEGF, comparing
the concentration of such a molecule in tear and blood
samples from VKC and control subjects. Tear samples are
relatively easy to collect from the patients as a noninvasive
diagnostic procedure that provides valuable information on
differential tear cytology and levels of mediators at the site of
inflammation [7, 10, 11]. (e critical limitation of such
a procedure is the volume of the tear sample, which ideally
should be collected without stimulating the tear reflex, and
the quantity of the sample obtainable, often very limited.
Determination of tear mediator, cytokine, or chemokine
levels is not yet used for diagnosis, but only for the study of
allergic physiopathology or for the evaluation of efficacy of
antiallergic agents [4, 7, 10, 11, 16]. (e concentration and
distribution of inflammatory mediators or inhibitors in the
tear fluid have been extensively studied in ocular allergy, in
an attempt to find a disease marker, to better understand the
immune mechanisms involved in the ocular surface in-
flammation and to identify potential targets for therapeutic
interventions [7, 8].
Epithelial cells, fibroblasts, and inflammatory cells in-
cluding eosinophils andmonocytes/macrophages are possible
sources of VEGF in VKC [7, 17]. Angiogenic and growth
factor pathological expression is frequently associated with
the expression ofmatrixmetalloproteases (MMPs) [7].MMPs
cause the extravasation of leukocytes through limited pro-
teolysis of basement membranes; degradation of pro-
teoglycans, laminin, fibronectin, and collagens; and activation
of the precursor forms of otherMMPs. An imbalance between
MMPs and their natural tissue inhibitors (TIMP) is also
probably involved in the pathogenesis of conjunctival in-
flammation, remodeling, and corneal changes in VKC. In fact,
MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, and MMP-10
are highly expressed in all forms of active VKC, consequently
to the increase of proinflammatory cytokines, such as IL-1b
and tumor necrosis factor-α (TNF-α) [7]. Moreover, chronic
conjunctival inflammation in VKC is associated with in-
creased expression of α3 and α6 integrin subunits’ receptors,
epidermal growth factor receptor (EGFR), VEGF, trans-
forming growth factor-b (TGF-b), basic fibroblast growth
factor (bFGF), and platelet-derived growth factor (PDGF),
thus suggesting a possible contribution of integrins, EGFR,
and growth factors in VKC conjunctival remodeling and also
a role of growth factors in the expression and function of
integrins [8].
On the other hand, an anti-VEGF therapy could be
helpful for anterior segment eye disease as an adjunct in the
treatment of allergic and immunologic eye diseases. (e
most important growth factor in corneal angiogenesis is
VEGF, and it is upregulated during corneal neo-
vascularization (NV). Recently, anti-VEGF therapies are one
of the most important drugs used for corneal NV treatment.
In fact, anti-VEGF therapies (bevacizumab, ranibizumab,
and aflibercept) have shown efficacy in attenuation of
corneal neovascularization in both animal models and
clinical trials [22, 23]. Case reports in this area include, for
example, topical bevacizumab use in a patient with long-
standing ocular cicatricial pemphigoid unresponsive to
steroid, but moderately responding to the treatment, a single
case of ocular graft-versus-host disease that responded
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partially to subconjunctival bevacizumab, and a report of
topical bevacizumab application in 2 patients with
Stevens–Johnson syndrome [22, 23]. Visual acuity improved
in all 3 eyes, with decreased corneal NV, haze, and con-
junctival injection without any serious adverse events. In
conclusion, bevacizumab has partially reduced corneal NV
through different routes of administrations: topical, sub-
conjunctival, and intraocular application, while early
treatment with subconjunctival administration of ranibi-
zumab may successfully reduce corneal NV. Establishment
of safe doses is highly important before these drugs can be
involved in the clinical setting [22, 23].
(us, VEGF becomes a potential marker for the disease
and/or its severity. It is our aim to cover in a future study
how the tear levels of such a mediator could possibly be
modified before and after treatment with therapeutic ocular
drops [4, 18–21]. When evaluating blood samples, the dif-
ference was not statistically significant. However, we found
a statistically significant difference of the VEGF concen-
tration in tears between VKC and control groups. Again, this
finding suggests the need for further studies, which should
include a larger number of patients suffering from VKC.
(en, VEGF concentration could be evaluated before and
after treatment with cyclosporine or anti-VEGF ocular drops
to investigation to better understand its role in the patho-
genesis of the disease. In summary, it might even be seen as
a potential therapeutic target.
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Figure 2: EIA values for VEGF concentration in tears and blood in control and vernal keratoconjunctivitis (VKC) groups.
TABLE 2: Comparisons of the 2 groups after using the VEGF EIA kit for vascular endothelial growth factor (VEGF) concentration.
VKC group (N � 21) Control group (N � 13) p value
VEGF tears in pg/mL: 12.13± 5.54 Tears in pg/mL: 7± 4.76 <0.05 (0.011)
VEGF serum in pg/mL: 45.17± 18.67 Serum in pg/mL: 38.08± 19.43 NS> 0.05 (0.29)
SD: standard deviation; NS: not statistically significant. (e values are expressed as mean ± SD. A statistically significant difference was found in tear samples
(p< 0.05). No statistically significant difference was found when comparing VEGF concentration in blood samples (p> 0.05).
Table 3: Pearson correlation coefficient (CC) results (parametric test) (statistical significance was set at p< 0.05).
VKC group (N � 21), mean value in pg/mL (±SD)
VEGF relationship Clinic score Pearson CC p value
Tears/giant papillae 12.13 (5.54) 3.43 (0.59) −0.14 <0.05
Tears/foreign body 12.13 (5.54) 3.24 (0.83) −0.18 <0.05
Tears/conjunctival hyperemia 12.13 (5.54) 2.76 (0.97) −0.15 <0.05
Tears/itching 12.13 (5.54) 2.57 (0.73) −0.12 <0.05
Serum/giant papillae 45.17 (18.67) 3.43 (0.59) −0.28 <0.05
Serum/foreign body 45.17 (18.67) 3.24 (0.83) 0.01 NS
Serum/conjunctival hyperemia 45.17 (18.67) 2.76 (0.97) 0.04 NS
Serum/itching 45.17 (18.67) 2.57 (0.73) −0.03 NS
NS: not statistically significant.
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